July 10, 2014 7:11 PM ET

Biotechnology

Company Overview of Cambrex Bio Science Walkersville, Inc.

Company Overview

Cambrex Bio Science Walkersville, Inc. engages in the manufacture and marketing of adult stem cell products for the life science research market. Its products include serum-free liquid media, micronized powdered medium, cell cultures, endotoxin detection products, Limulus Amebocyte Lysate products, sera, reagents, human cell systems, research and therapeutic media, electrophoresis, and chromatography products. The company provides custom manufacturing and cell therapy services. It also supplies culture media for the production of human adult stem cells in therapeutic applications. In addition, it offers software and equipment. The company serves biotechnology, clinical, pharmaceutical, and r...

8830 Biggs Ford Road

Walkersville, MD 21793

United States

Phone:

301-898-7025

Fax:

301-845-4024

Key Executives for Cambrex Bio Science Walkersville, Inc.

Chief Executive Officer
Age: 80
Chief Financial Officer
Age: 57
Chief Operating Officer
Age: 71
General Counsel and Corporate Secretary
Age: 66
Vice President - Regulatory Affairs
Age: 64
Compensation as of Fiscal Year 2014.

Cambrex Bio Science Walkersville, Inc. Key Developments

Lonza Walkersville and Hyglos Signs Mutually Beneficial Global Settlement Deal and Licensing Agreement

Lonza Walkersville and Hyglos have signed a mutually beneficial global settlement deal that includes a licensing agreement for endotoxin detection patents. According to the deal, Hyglos will leverage Lonza's patent-protected recombinant factor C technology in the production of endotoxin products. As part of the settlement, Lonza will cancel a previously filed lawsuit against Hyglos.

Lonza Walkersville, Inc. Wins $6.9 Million Contract

The National Institutes of Health Center for Regenerative Medicine has awarded Lonza Walkersville, Inc. (Cambrex Bio Science Walkersville, Inc.) a contract to generate induced pluripotent stem cells (iPSCs) for research purposes. This is the second contract the NIH has awarded Lonza for the generation of induced pluripotent stem cells (iPSCs). The Lonza contract is a three year agreement with a value up to $6.9 million.

Cambrex Bio Science Walkersville, Inc. Receives Contract to Generate Clinical Grade iPSCs by National Institutes of Health Center for Regenerative Medicine

The National Institutes of Health Center for Regenerative Medicine has awarded Cambrex Bio Science Walkersville, Inc. a contract to generate induced pluripotent stem cells (iPSCs) under current Good Manufacturing Practices (cGMP). The production of clinical grade iPSCs is considered a critical component to realizing the therapeutic potential of pluripotent stem cells. The contract also includes manufacturing of clinical grade iPSC-derived cell types.

Similar Private Companies By Industry

Company Name Region
N8 Medical, LLC United States
Algal Scientific Corporation United States
Carepeutics, Inc. United States
Vesta Therapeutics, Inc. United States
SoluLinK, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cambrex Bio Science Walkersville, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.